PMA device
Transcyte
Shire Regenerative Medicine · Dressing, Wound And Burn, Interactive (MGR, Class III) · First FDA decision Mar 16, 2000, newest Jun 28, 2004BurnsChronic wounds and ulcers
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
1
Naming "Transcyte"
MAUDE reports
1
Brand "Transcyte", since 2015
PubMed studies
17
Mentioning "Transcyte"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Transcyte
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 3 decisions filed under this name.
- TRANSCYTEPMA supplement
P960007-S017 · Decided Jun 28, 2004 · 676 days after receipt · Normal 180 Day Track No User Fee
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
- TRANSCYTE(TM)PMA supplement
P960007-S014 · Decided May 19, 2000 · 79 days after receipt · Normal 180 Day Track
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Transcyte", any status and sponsor, newest update first.
- The Diabetic Foot Ulcer RegistryStatus unknown
U.S. Wound RegistryAcademic, hospital or other
NCT02813161 · 10,000 participants (planned) · Start Feb 2015 · Primary completion Jan 2025
Device: negative pressure wound therapy; off-loading and 1 more · For: Diabetic Foot Ulcer Outcome; Quality of Patient Care
Sites: The Woodlands, Texas
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Transcyte", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 0 injury, 0 death
Whole product code MGR
11 reports: 1 malfunction, 9 injury, 0 death
Newest reports for this brand
- TRANSCYTENot stated
9840585 · Received Mar 17, 2020 · Event dated Feb 21, 2020
Device type: Dressing, Wound And Burn, Interactive (MGR)
Device problem as coded: Expiration Date Error
Patient problem as coded: No Known Impact Or Consequence To Patient
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Transcyte"[tiab]. The summary above synthesizes these.
- Effectiveness of Dermal Regeneration Templates in Managing Acute Full-thickness and Deep Dermal Burn Injuries: A Comparison with Split-thickness Skin Grafts.
Alkhonizy SW, Sabbah BN, Khader MS, et al. · Plast Reconstr Surg Glob Open · 2024
- The use of a bioactive skin substitute decreases length of stay for pediatric burn patients.
Lukish JR, Eichelberger MR, Newman KD, et al. · J Pediatr Surg · 2001Comparative Study
- Bioengineered skin substitutes for the management of burns: a systematic review.
Pham C, Greenwood J, Cleland H, et al. · Burns · 2007Systematic Review
- Topical treatment for facial burns.
Hoogewerf CJ, Hop MJ, Nieuwenhuis MK, et al. · Cochrane Database Syst Rev · 2020Research Support, Non-U.S. Gov't, Systematic Review
- Safety and efficacy of TransCyte for the treatment of partial-thickness burns.
Noordenbos J, Doré C, Hansbrough JF · J Burn Care Rehabil · 1999Clinical Trial, Comparative Study
- Efficacy Of Skin Substitutes For Management Of Acute Burn Cases: A Systematic Review.
Wardhana A, Valeria M · Ann Burns Fire Disasters · 2022
- Guiding practice improvements in pediatric surgery using multidisciplinary clinical pathways.
Johnson PA, Chavanu KE, Newman KD · Semin Pediatr Surg · 2002
- Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte.
Kumar RJ, Kimble RM, Boots R, et al. · ANZ J Surg · 2004Clinical Trial, Comparative Study
- Tissue-engineered skin. Current status in wound healing.
Bello YM, Falabella AF, Eaglstein WH · Am J Clin Dermatol · 2001Review
- Tissue-engineered temporary wound coverings. Important options for the clinician.
Ehrenreich M, Ruszczak Z · Acta Dermatovenerol Alp Pannonica Adriat · 2006Review
- Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes).
Demling RH, DeSanti L · Burns · 1999Clinical Trial, Comparative Study
- New Topical Agents for Treatment of Partial-thickness Burns in Children: A Review of Published Outcome Studies .
Dorsett-Martin WA, Persons B, Wysocki A, et al. · Wounds · 2008
Other devices of this type
Also filed under product code MGR.
- ApligrafOrganogenesis, Inc. · PMA 2013
- DermagraftShire Regenerative Medicine · PMA 2012
- Integra Dermal Regeneration TemplateIntegra Lifesciences Corp. · PMA 2017
- Transcyte Human Fibroblast-Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2011
- Apilgraf(Graftskin)Organogenesis, Inc. · PMA 2002
- Orcel Bilayered Cellular MatrixForticell Bioscience · PMA 2001
- Transcyte/Human Fibroblast Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.